Patients with systemic sclerosis often seek information regarding complementary and nutrition-based therapy. Some study results have shown that vitamins D and E, probiotics, turmeric, l-arginine, essential fatty acids, broccoli, biofeedback, and acupuncture may be beneficial in systemic sclerosis care. However, large randomized clinical trials have not been conducted. This review summarizes current data regarding various complementary therapies in systemic sclerosis and concludes with recommendations.
HunnicuttSEGradyJMcNearneyTA.Complementary and alternative medicine use was associated with higher perceived physical and mental functioning in early systemic sclerosis. Explore2008; 4(4): 259–263.
2.
MooreADPetriMAManziS, et al. The use of alternative medical therapies in patients with systemic lupus erythematosus. Arthritis Rheum2000; 43(6): 1410–1418.
3.
HolickMF.Vitamin D deficiency. N Engl J Med2007; 357: 266–281.
4.
PelajoCFLopez-BenitezJMMillerLC.Vitamin D and autoimmune rheumatologic disorders. Autoimmun Rev2010; 9(7): 507–510.
5.
AranowC.Vitamin D and the immune system. J Investig Med2011; 59: 881–886.
6.
JoshiSPantalenaLCLiuXK, et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol2011; 31(17): 3653–3669.
7.
PrietlBTreiberGPieberTR, et al. Vitamin D and immune function. Nutrients2013; 5: 2502–2521.
8.
VaccaACormierCPirasM, et al. Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J Rheumatol2009; 36(9): 1924–1929.
9.
OrbachHZandman-GoddardGAmitalH, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci2007; 1109: 385–400.
10.
ZoldESzodorayPGaalJ, et al. Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther2008; 10: R123.
11.
MontaboneEDataVCarignolaR.Vitamin D status and quality of life in systemic sclerosis patients. J Clin Rheumatol2016; 22(4): 229–230.
12.
Sampaio-BarrosMMTakayamaLSampaio-BarrosPD, et al. Low vitamin D serum levels in diffuse systemic sclerosis: a correlation with worst quality of life and severe capillaroscopic findings. Rev Bras Reumatol Engl Ed2016; 56(4): 337–344.
13.
TrombettaACSmithVGotelliE, et al. Vitamin D deficiency and clinical correlations in systemic sclerosis patients: a retrospective analysis for possible future developments. PLoS ONE2017; 12(6): e0179062.
14.
CalzolariGDataVCarignolaR, et al. Hypovitaminosis D in systemic sclerosis. J Rheumatol2009; 36: 2844, author reply 5.
15.
LeFevreML and U.S. Preventive Services Task Force. Screening for vitamin D deficiency in adults: U.S. Ann Intern Med2015; 162(2): 133–140.
16.
Rios FernandezRFernandez RoldanCCallejas RubioJL, et al. Vitamin D deficiency in a cohort of patients with systemic scleroderma from the south of Spain. J Rheumatol2010; 37: 1355, author reply 6.
17.
GallagherJCSaiATemplinT2nd, et al. Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann Intern Med2012; 156(6): 425–437.
18.
ChungLFiorentinoD.Digital ulcers in patients with systemic sclerosis. Autoimmun Rev2006; 5: 125–128.
19.
AbrahamSSteenV.Optimal management of digital ulcers in systemic sclerosis. Ther Clin Risk Manag2015; 11: 939–947.
20.
FioriGGalluccioFBraschiF, et al. Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis. Clin Exp Rheumatol2009; 27(3Suppl. 54): 51–54.
21.
WuDLiuLMeydaniM, et al. Vitamin E increases production of vasodilator prostanoids in human aortic endothelial cells through opposing effects on cyclooxygenase-2 and phospholipase A2. J Nutr2005; 135(8): 1847–1853.
22.
LebedoffNFrechTShanmugamV, et al. Review of local wound management for scleroderma-associated digital ulcers. J Scleroderm Relat Disord2017; 3: 66–70.
23.
MorelliSSgrecciaABernardoML, et al. Systemic sclerosis (scleroderma). A case of recovery of cardiomyopathy after Vitamin E treatment. Minerva Cardioangiol2001; 49: 127–130.
24.
CracowskiJLGiroletSImbertB, et al. Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement. Free Radic Biol Med2005; 38(1): 98–103.
25.
LeyREPetersonDAGordonJI.Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell2006; 124(4): 837–848.
26.
MasonKLHuffnagleGBNoverrMC, et al. Overview of gut immunology. Adv Exp Med Biol2008; 635: 1–14.
27.
SekirovIRussellSLAntunesLC, et al. Gut microbiota in health and disease. Physiol Rev2010; 90: 859–904.
28.
MazmanianSKLiuCHTzianabosAO, et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell2005; 122(1): 107–118.
29.
FinkLNZeuthenLHChristensenHR, et al. Distinct gut-derived lactic acid bacteria elicit divergent dendritic cell-mediated NK cell responses. Int Immunol2007; 19(12): 1319–1327.
30.
PillaiANelsonR.Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev2008; 1: CD004611.
31.
BrennerDMMoellerMJCheyWD, et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol2009; 104(4).
32.
BraatHRottiersPHommesDW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol2006; 4(6): 754–759.
33.
LonnermarkEFrimanVLappasG, et al. Intake of Lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment with antibiotics. J Clin Gastroenterol2010; 44(2): 106–112.
34.
FrechTMKhannaDMaranianP, et al. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention. Clin Exp Rheumatol2011; 29(2Suppl. 65): S22–S25.
35.
RautavaSSalminenSIsolauriE.Specific probiotics in reducing the risk of acute infections in infancy—a randomised, double-blind, placebo-controlled study. Br J Nutr2009; 101(11): 1722–1726.
36.
MieleEPascarellaFGiannettiE, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol2009; 104(2): 437–443.
37.
DeGreefEVandenplasYHauserB, et al. The use of probiotics in IBD and IBS. Minerva Pediatr2014; 66(5): 491–500.
38.
JonkersDStockbruggerR.Probiotics and inflammatory bowel disease. J R Soc Med2003; 96: 167–171.
39.
BatesJMAkerlundJMittgeE, et al. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell Host Microbe2007; 2(6): 371–382.
40.
GareauMGShermanPMWalkerWA.Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol2010; 7(9): 503–514.
41.
VolkmannERHoffmann-VoldAMChangYL, et al. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterol2017; 4(1): e000134.
42.
VolkmannERChangYLBarrosoN, et al. Association of systemic sclerosis with a unique colonic microbial consortium. Arthritis Rheumatol2016; 68(6): 1483–1492.
43.
PopeJ.Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler’s Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud’s Condition Score (RCS). Arthritis Care Res2011; 63(Suppl. 11): S98–S111.
44.
Enteshari-MoghaddamAMovassaghiSRostamianA.Effect of probiotics in the treatment of gastrointestinal symptoms in patients with scleroderma. Intj Sci Rep2016; 2: 5.
45.
VenugopalanVShrinerKAWong-BeringerA.Regulatory oversight and safety of probiotic use. Emerg Infect Dis2010; 16(11): 1661–1665.
46.
European Food Safety Authority. Nutrition and Health Claims. European Union: EFSA, 2012.
47.
ZhouHBeeversCSHuangS.The targets of curcumin. Curr Drug Targets2011; 12: 332–347.
48.
SongKPengSSunZ, et al. Curcumin suppresses TGF-beta signaling by inhibition of TGIF degradation in scleroderma fibroblasts. Biochem Biophys Res Commun2011; 411(4): 821–825.
49.
AggarwalBBHarikumarKB.Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol2009; 41(1): 40–59.
50.
AggarwalSIchikawaHTakadaY, et al. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol2006; 69(1): 195–206.
51.
ParkCMoonDOChoiIW, et al. Curcumin induces apoptosis and inhibits prostaglandin E(2) production in synovial fibroblasts of patients with rheumatoid arthritis. Int J Mol Med2007; 20(3): 365–372.
52.
GaedekeJNobleNABorderWA.Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells. Kidney Int2004; 66(1): 112–120.
53.
LiRWangYLiuY, et al. Curcumin inhibits transforming growth factor-beta1-induced EMT via PPARgamma pathway, not Smad pathway in renal tubular epithelial cells. PLoS ONE2013; 8: e58848.
54.
KawakamiTIhnHXuW, et al. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol1998; 110(1): 47–51.
55.
AnandPKunnumakkaraABNewmanRA, et al. Bioavailability of curcumin: problems and promises. Mol Pharm2007; 4(6): 807–818.
56.
ChengALHsuCHLinJK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res2001; 21: 2895–2900.
57.
KimDCKuSKBaeJS. Anticoagulant activities of curcumin and its derivative. BMB Rep2012; 45(4): 221–226.
58.
CurtissPSchwagerZLoSiccoK, et al. The clinical effects of l-arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud’s phenomenon. J Eur Acad Dermatol Venereol. Epub ahead of print 13 July 2018. DOI: 10.1111/jdv.15180.
59.
CottonSAHerrickALJaysonMI, et al. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol1999; 189(2): 273–278.
60.
Matucci CerinicMKahalehMB. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology2002; 41: 843–847.
61.
DimitroulasTGiannakoulasGSfetsiosT, et al. Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology2008; 47(11): 1682–1685.
62.
RajagopalanSPfenningerDKehrerC, et al. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud’s phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum2003; 48(7): 1992–2000.
63.
SchwedhelmEMaasRFreeseR, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol2008; 65(1): 51–59.
64.
WipffJAvouacJBorderieD, et al. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology2008; 47(7): 972–975.
65.
DooleyAGaoBBradleyN, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology2006; 45(6): 676–684.
66.
RemboldCMAyersCR.Oral L-arginine can reverse digital necrosis in Raynaud’s phenomenon. Mol Cell Biochem2003; 244(1–2): 139–141.
67.
GiuggioliDColaciMSebastianiM, et al. L-Arginine in pregnant scleroderma patients. Clin Rheumatol2010; 29(8): 937–939.
68.
KhanFBelchJJ.Skin blood flow in patients with systemic sclerosis and Raynaud’s phenomenon: effects of oral L-arginine supplementation. J Rheumatol1999; 26(11): 2389–2394.
69.
ScholkensBAGehringDSchlotteV, et al. Evening primrose oil, a dietary prostaglandin precursor, diminishes vascular reactivity to renin and angiotensin II in rats. 1982; 8(3): 273–285.
70.
vonSchackyCFischerSWeberPC.Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest1985; 76(4): 1626–1631.
71.
StainforthJMLaytonAMGoodfieldMJ.Clinical aspects of the use of gamma linolenic acid in systemic sclerosis. Acta Derm Venereol1996; 76(2): 144–146.
72.
DiGiacomoRAKremerJMShahDM.Fish-oil dietary supplementation in patients with Raynaud’s phenomenon: a double-blind, controlled, prospective study. Am J Med1989; 86(2): 158–164.
73.
BelchJJShawBO’DowdA, et al. Evening primrose oil (Efamol) in the treatment of Raynaud’s phenomenon: a double blind study. Thromb Haemost1985; 54(2): 490–494.
74.
MalenfantDCattonMPopeJE.The efficacy of complementary and alternative medicine in the treatment of Raynaud’s phenomenon: a literature review and meta-analysis. Rheumatology2009; 48(7): 791–795.
75.
ArumugamAAbdullRazisAF.Apoptosis as a mechanism of the cancer chemopreventive activity of glucosinolates: a review. Asian Pac J Cancer Prev2018; 19(6): 1439–1448.
76.
WeiJZhuHLordG, et al. Nrf2 exerts cell-autonomous antifibrotic effects: compromised function in systemic sclerosis and therapeutic rescue with a novel heterocyclic chalcone derivative. Transl Res2017; 183: 71–86e1.
77.
McWalterGKHigginsLGMcLellanLI, et al. Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. J Nutr2004; 134(12 Suppl.): 3499S–3506S.
78.
JugeNMithenRFTrakaM.Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci2007; 64(9): 1105–1127.
79.
KobayashiEHSuzukiTFunayamaR, et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun2016; 7: 11624.
80.
HwangJHLimSB. Antioxidant and anti-inflammatory activities of broccoli florets in LPS-stimulated RAW 264.7 cells. Prev Nutr Food Sci2014; 19(2): 89–97.
81.
FuentesFParedes-GonzalezXKongAN.Dietary glucosinolates sulforaphane, phenethyl isothiocyanate, Indole-3-Carbinol/3,3’-Diindolylmethane: anti-oxidative stress/inflammation, Nrf2, epigenetics/epigenomics and in vivo cancer chemopreventive efficacy. Curr Pharmacol Rep2015; 1(3): 179–196.
82.
TownsendBEChenYJJefferyEH, et al. Dietary broccoli mildly improves neuroinflammation in aged mice but does not reduce lipopolysaccharide-induced sickness behavior. Nutr Res2014; 34: 990–999.
83.
Does Broccoli Hold the Key to Halting Fibrosis? 5 ed. Northwestern Scleroderma Program Bulletin, Winter 2015; 5(1).
84.
SedlacekK.Biofeedback for Raynaud’s disease. Psychosomatics1979; 20: 5358–5341.
85.
NeblettR.Surface Electromyographic (SEMG) biofeedback for chronic low back pain. Healthcare2016; 4(2).
86.
Investigators RTS. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med2000; 160: 1101–1108.
87.
SporbeckBMathiske-SchmidtKJahrS, et al. Effect of biofeedback and deep oscillation on Raynaud’s phenomenon secondary to systemic sclerosis: results of a controlled prospective randomized clinical trial. Rheumatol Int2012; 32(5): 1469–1473.
88.
JahrSSchoppeBReisshauerA.Effect of treatment with low-intensity and extremely low-frequency electrostatic fields (Deep Oscillation) on breast tissue and pain in patients with secondary breast lymphoedema. J Rehabil Med2008; 40(8): 645–650.
89.
AmmendoliaCFurlanADImamuraM, et al. Evidence-informed management of chronic low back pain with needle acupuncture. Spine J2008; 8(1): 160–172.
90.
ZhouWBenharashP.Effects and mechanisms of acupuncture based on the principle of meridians. J Acupunct Meridian Stud2014; 7(4): 190–193.
91.
WollastonDEXuXTokumaruO, et al. Patients with systemic sclerosis have unique and persistent alterations in gastric myoelectrical activity with acupressure to Neiguan point PC6. J Rheumatol2005; 32(3): 494–501.
92.
SallamHSMcNearneyTAChenJD.Acupuncture-based modalities: novel alternative approaches in the treatment of gastrointestinal dysmotility in patients with systemic sclerosis. Explore2014; 10(1): 44–52.
93.
KarataySUzkeserH. Beneficial Acupuncture Treatment For Systemic Sclerosis which was Non-Responsive To Medications. Acupunct Electrother Res2015; 40(3): 205–214.
94.
MaedaMKachiHIchihashiN, et al. The effect of electrical acupuncture-stimulation therapy using thermography and plasma endothelin (ET-1) levels in patients with progressive systemic sclerosis (PSS). J Dermatol Sci1998; 17(2): 151–155.
